Featured Story | By Kyle LaHucik Zai Lab is teaming up with MacroGenics a second time, after their initial 2018 collaboration, on four bispecific antibodies. The deal comes two months after Zai said it would offer $750 million in American depository shares to fund business and product development as well as deals. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus CAR-T therapies are heating up, with two new approvals in the past year, but the drug class has been limited to blood cancers and can run into resistance issues. Mnemo Therapeutics thinks it has a solution, and a new funding round of €75 million ($90 million) will help get that plan rolling. read more By Nick Paul Taylor Kahr has raised $46.5 million to move a CD47x4-1BB targeting fusion protein deeper into the clinic. The size of the financing leaves Kahr with enough money left over to take a TIGITxPD-1 asset through IND-enabling studies. read more Sponsored by: RBC Capital Markets Take a closer look at the SPAC phenomenon with Dr. David Hung, Founder and CEO of Nuvation Bio and Michelle Doig, Omega Funds Partner and President of its Omega Alpha SPAC. read more By Kyle LaHucik Elanco's pet health M&A spree since separating from Eli Lilly in 2019 continued Wednesday with a $440 million agreement to buy Kindred Biosciences for its pipeline of pet dermatology and other products. KindredBio gives Elanco three potential blockbusters in dermatology that are expected to come to market through 2025, which is slated to provide Elanco an additional $100 million in innovation revenue by that year. read more By Amirah Al Idrus After running a research hub in San Francisco for more than 10 years, Bayer is leaving the city. The company is working with startups that have taken up residence in its incubator space in San Francisco to find new homes and encouraged employees at the site to apply for other jobs within the company, including at its nearby site in Berkeley. read more By Amirah Al Idrus Four years after launching Alivio Therapeutics, PureTech Health is bringing the hydrogel player back into the fold by acquiring the remaining 22% of the company. Through the deal, PureTech will add Alivio’s programs for inflammatory diseases to its own pipeline, including LYT-500, an oral treatment for inflammatory bowel disease (IBD). read more By Nick Paul Taylor Molecular Partners has priced its IPO, setting it up to raise $63.8 million to fund work on oncology and infectious disease candidates. The IPO haul is set to fall well short of the original target after a five-day period in which the biotech’s share price in Switzerland fell 17%. read more By Eric Sagonowsky Amid COVID-19 lockdowns, routine cancer screenings were put on the back burner. While that may be a short-term harm from the pandemic, the crisis also showed the world that science can solve tough problems, a Johnson & Johnson exec said, and that could bring long-term wins in oncology. read more By Kyle LaHucik German biotech-CRO hybrid Evotec is launching a new program linking up resources across the antiviral therapeutics development chain to fight the “permanent global threat" of a pandemic. read more By Andrea Park Though the first confirmed domestic case of COVID-19 was announced Jan. 21, 2020, new research from the NIH indicates that the coronavirus made its way to the U.S. shores well before that—at least as early as December 2019—reaching far beyond the initial hotspots of Washington state and New York. read more |  | LabConnect is the leader in innovative central laboratory services for cell and gene therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today. |
Resources Sponsored by: Thermo Fisher Scientific Learn how the diagnostics industry is being fundamentally transformed with point-of-care molecular testing. Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
